Phosphonic acid, diammonium salt, monohydrate

Skin irritation / corrosion

Administrative data

Endpoint:

skin irritation: in vitro / ex vivo

Type of information:

other: Read Across from supporting substance

Adequacy of study:

key study

Study period:

From 17th January 2013 to 11th of March

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

other: GLP study, well conducted on the similar substance Reaction mass of dipotassium phosphonate and Phosphonic acid, potassium salt (1:1). Rationale for Read Across is attached at point 13

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

2013

Materials and methods

Test guideline

Test guideline 1

Qualifier:

according to guideline

Guideline:

OECD Guideline 439 (In Vitro Skin Irritation: Reconstructed Human Epidermis Test Method)

Test guideline 2

Qualifier:

according to guideline

Guideline:

other: Commission Regulation (EC) No. 761/2009 amending Regulation (EC) No. 440/2008, B.46 “In Vitro Skin Irritation: Reconstructed Human Epidermis Model Test

GLP compliance:

yes (incl. QA statement)

Test material

Test material information

Constituent 1

Reference substance name:

Potassium Phosphonate KH2PO3/K2HPO3

IUPAC Name:

Potassium Phosphonate KH2PO3/K2HPO3

Test material form:

other: liquid

Details on test material:

- Name of test material: potassium phosphonate KH2PO3/K2HPO3
- Substance type: inorganic
- Physical state: clear free-flowing white/colourless solution
- Storage condition of test material: ambient condition
- Stability: no assay of test item stability, nor its concentration and homogeneity in solvent were undertaken
- Expiration date of the lot/batch: 16/12/2013
- Preparation: the test item was used in the form supplied, without any further dilution. No analysis was carried out.

Test animals

Species:

other: in vitro

Details on test animals or test system and environmental conditions:

In vitro test

Test system

Type of coverage:

other: in vitro

Amount / concentration applied:

20 μL/well (see table 1)

Duration of treatment / exposure:

15 ± 0.5 minutes was allowed in a ventilated cabinet at room temperature.
Treatment was carried out staggering samples of approximately 1 minute.
Positive control: an intermediate re-spreading was carried out approximately after 7 minutes of incubation.
A 42 hour recovery period

Number of animals:

In vitro

Details on study design:

The test system EPISKIN™ is a reconstructed human epidermis (RhE) model, which in its overall design (the use of human derived epidermis keratinocytes as cell source and use of representative tissue and cytoarchitecture) closely mimics the biochemical and physiological properties of the upper parts of the human skin, i.e., the epidermis.
The principle of the RhE test method is based on the premise that chemicals are able to penetrate the stratum corneum and irritant chemicals are cytotoxic to the cells in the underlying layers. Cell viability is measured by dehydrogenase conversion of the vital dye MTT [3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, Thiazolyl blue; CAS RN 298-93-1] into a blue formazan salt that is quantitatively measured after extraction from tissues. Irritant chemicals are identified by their ability to decrease cell viability below defined threshold levels.

Test System: EPISKIN™
Commercial Name: EPISKINTM - 0.38 cm2
Supplier: SkinEthic Laboratories (4, A. Fleming – 69007 Lyon – France).
Batch: 13-EKIN-008
Arrived at RTC: 05 March 2013
Functional controls: Quality controls: histology scoring, magnitude of viability and barrier function (IC50 determination).
Biological safety: absence of HIV1 and 2, Hepatitis B and C antigens, absence of bacteria, fungi and mycoplasma.
A certificate of analysis can be found in Addendum III.

Preparation of the Test System
Examination at arrival
Temperature indicator: pale grey (suitable for use)
pH indicator: orange (suitable for use)
Placing in culture: according to the supplier procedure, the test system was shipped on Monday and received on Tuesday. At arrival, the plate was openedunder a sterile airflow and each insert, containing the epidermal tissue, was carefully taken out and placed in a 12-well plate (supplied) in which each well had previously been filled with 2 mL/well SkinEthic Maintenance Medium.
Pre-treatment incubation period: culture dishes were placed in the incubator at 37°C, 5% CO2 and saturated humidity for approximately 24 hours.

Media
SkinEthic Maintenance Medium: SkinEthic; batch: 13-MAIN3-011
SkinEthic Assay Medium: SkinEthic; batch: 13-ESSC-002 and 13-ESSC-009
Dulbecco’s Phosphate buffered saline (D-PBS): GIBCO; batch: 1098754
Sterile water: Baxter; batch: 12D1810
MTT Reagent:Sigma; batch: MKBB1495
MTT Stock Solution: MTT Reagent 3 mg/mL in D-PBS
Stored at ambient conditions, protected from light; used on the day of dilution
MTT Ready-to-use Solution: MTT Stock Solution diluted 1:10 (v/v) with SkinEthic Assay Medium (final concentration 0.3 mg/mL of MTT)
Stored at ambient conditions, protected from light. Used within 1 hour from preparation
Acidic Isopropanol
(0.04 N HCl in isopropanol): 12 N HCl (Fluka; batch: 0001434790) added to
2-propanol (BDH; batch: 09D170512)
Stored at ambient conditions
Used within 1 month from preparation

Experimental procedure
Preliminary test
Direct MTT reduction test (Step 1) : Non-specific reduction of MTT was evaluated as follows: two mL of MTT Ready-to-use Solution was incubated with 20 µL of test item at 37°C, 5% CO2 and saturated humidity for 3 hours protected from light, simulating test conditions. Observation of blue or purple appearance of the solution at the end of the incubation time was carried out.
Colouring potential test (Step 2): Chemicals’ colouring potential was assessed for potential interaction with the test system.
10 μL of the test item was added to 90 µL of distilled water in a transparent tube and the resulting solution/suspension mixed by using a vortex for 15 minutes.
Colouring of the solution at the end of the incubation time was evaluated.

Main Assay
Treatment: A Main Assay was carried out including the test item, positive and negative controls. Sample Test System Treatment are reported in table 1.
Washing: At the end of the exposure, each tissue was rinsed with approximately 25 mL of sterile D-PBS filling and empting the tissue insert.
The excess liquid was carefully removed and the sample transferred in new wells pre-filled with 2 mL/well of maintenance medium.
Post-exposure period: A 42 hour recovery period was allowed by incubation at 37°C, 5% CO2 and saturated humidity.
Media collection for further analysis: At the end of the incubation period, the plates were shaked on a plate shaker for about 15 minutes at approximately 300 rpm/min.
A volume of 1.6 mL of each incubation medium was removed and stored at 20°C for possible future analysis.These samples were not analysed.

MTT Assay: The tissue insert and controls were incubated with 2 mL/well of MTT ready-to-use solution for approximately 3 hours at 37°C, 5% CO2 and saturated humidity.
At the end of the incubation period, tissues were placed on absorbent paper to dry. A total biopsy was carried out by means of a biopsy punch to allow biopsies of the same dimensions.
The epidermis were separated from the collagen matrix and both placed in a microtube prefilled with 500 μL of acidic isopropanol.
Tubes were mixed by vortexing and preserved for approximately 3 days at 4°C to allow formazan extraction.
At the end of the extraction period, debris were eliminated by short centrifugation of the tubes (approximately 14000 rpm for 2 minutes) and aliquots of 200 µL from each sample were read in duplicate for their absorbance at 595 nm. OD values were recorded. Six aliquots (200 μL) of acidic isopropanol were analysed and used as blank.

Results and discussion

In vitro

Results

Irritation / corrosion parameter:

other: other: Viability index

Value:

> 92.1

Remarks on result:

other:

Remarks:

Basis: mean. Time point: 3h. Max. score: 100.0. Reversibility: other: Not applicable. Remarks: A value > 50 indicates no irritation potential. (migrated information)

Any other information on results incl. tables

Table 2. Preliminary test

Direct MTT reduction test (Step 1)
Test item (mL)	MTT ready to use solution (mL)	Container	Incubation condition	Colour Observation
20	2.0	well	3 h at 37°C, 100% nominal humidity, 5% CO2	Yellowish (no interaction)
Colouring potential test (Step 2)
Test item (mL)	MTT ready to use solution (mL)	Container	Incubation condition	Colour Observation
10	90	Eppendorf tube	15’, ambient condition, in agitation	Colourless solution

Table 3. Main test

Test	Viability%
Blank (negative control)	100
Positive control	4.3
Test Item A	92.1

Applicant's summary and conclusion

Interpretation of results:

not irritating

Remarks:

Migrated information Criteria used for interpretation of results: EU

Conclusions:

The potential of the test item Potassium phosphonate KH2PO3/KH2PO3 to be irritant to the skin was investigated through an in vitro skin irritation study, using a commercial reconstructed human epidermis (RhE) model named EPISKINTM. Based on the mean cell viability (92.1%) when compared to the negative control, the test item should be considered not irritant. The negative and positive controls gave the expected results and the study was accepted as valid.

Executive summary:

The potential of the test item Potassium phosphonate KH2PO3/KHPO3 to be irritant to the skin was investigated through anin vitroskin irritation study using a commercial reconstructed human epidermis (RhE) model named EPISKIN^TM. The experimental procedures are based on the OECD Guideline for testing of chemicals no. 439.

The test item, as well as controls, were tested for their ability to impair cell viability after an exposure period of 15 minutes followed by a 42 hour recovery period.The final endpoint of the assay is the colorimetric measurement of MTT reduction (blue formazan salt) in the test system being this reaction an index of cell viability.

Before the Main Assay, a preliminary test was carried out to evaluate the compatibility of the test item with the test system. In particular, the test item was assayed for the ability of reducing MTT and colouring waterper se.

No interaction was recorded between the test item and MTT in test conditions similar to those of the Main Assay. Moreover, no colouring potential of the test item in contact with water was recorded. Thus, no additional control was added in the main phase for the evaluation of non specific colour generation which may influence evaluation of results.

In the Main Assay,the test item was applied as supplied in three replicates at the treatment level of 20mL/epidermisunit, each measuring 0.38 cm²(treatment level: 53mL/cm²).

Positive and negative controls [a 5% (w/v) sodium dodecyl sulphate solution in water and Dulbecco’s phosphate buffered saline (D-PBS), respectively] were concurrently tested, in the same number of replicates and test conditions at the treatment level of 20mL/epidermisunit.

The negative control gave the expected baseline value (Optical Density values of the three replicates higher than 0.6) and variability [Standard Deviation (SD) of % viability lower or equal to 18], in agreement with the guideline indications. According to the method, the mean value is considered the baseline value of the experiment and thus represents 100% of cell viability.       

The positive control caused the expected cell death (4.3% of cell viability when compared to the negative control) and variability (SD of % viability equal to 0.5).

Based on the stated criteria: mean viability ≤ 40% and SD of % viability ≤ 18, the assay was regarded as valid.       

The test item did not induce cell death in any replicate with a mean cell viability of 92.1% when compared to the negative control. Intra-replicate variability was acceptable with a SD of % viability value equal to 5.2 (lower than 18).

Based on the results obtained, the test itemPotassium phosphonate – Multicomponentis classified as not irritant to the skin.